Dyslipidemia, statins and prostate cancer

References

• Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J. Clin.61(4), 212–236 (2011).
   PubMed Web of Science ®Google Scholar
• Platz EA, Rimm EB, Willett WC, Kantoff PW, Giovannucci E. Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals. J. Natl Cancer Inst.92(24), 2009–2017 (2000).
   PubMed Web of Science ®Google Scholar
• Whittemore AS, Wu AH, Kolonel LN et al. Family history and prostate cancer risk in black, white, and Asian men in the United States and Canada. Am. J. Epidemiol.141(8), 732–740 (1995).
   PubMed Web of Science ®Google Scholar
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of The National Cholesterol Education Program (NCEP) Expert Panel On Detection, Evaluation, And Treatment Of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA285(19), 2486–2497 (2001).
   PubMed Web of Science ®Google Scholar
• Moradi T, Delfino RJ, Bergstrom SR, Yu ES, Adami HO, Yuen J. Cancer risk among Scandinavian immigrants to the US and Scandinavian residents compared with US whites, 1973-1989. Eur. J. Cancer Prev.7(2), 117–125 (1998).
   PubMed Web of Science ®Google Scholar
• Ghandehari H, Kamal-Bahl S, Wong ND. Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003–2004. Am. Heart J.156(1), 112–119 (2008).
   PubMed Web of Science ®Google Scholar
• Mann D, Reynolds K, Smith D, Muntner P. Trends in statin use and low-density lipoprotein cholesterol levels among US adults: impact of the 2001 National Cholesterol Education Program guidelines. Ann. Pharmacother.42(9), 1208–1215 (2008).
   PubMed Web of Science ®Google Scholar
• Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet366(9493), 1267–1278 (2005).
   PubMed Web of Science ®Google Scholar
• Magura L, Blanchard R, Hope B, Beal JR, Schwartz GG, Sahmoun AE. Hypercholesterolemia and prostate cancer: a hospital-based case–control study. Cancer Causes Control19(10), 1259–1266 (2008).
   PubMed Web of Science ®Google Scholar
• Platz EA, Till C, Goodman PJ et al. Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol. Biomarkers Prev.18(11), 2807–2813 (2009).
   PubMed Web of Science ®Google Scholar
• Platz EA, Clinton SK, Giovannucci E. Association between plasma cholesterol and prostate cancer in the PSA era. Int. J. Cancer123(7), 1693–1698 (2008).
   PubMed Web of Science ®Google Scholar
• Mondul AM, Clipp SL, Helzlsouer KJ, Platz EA. Association between plasma total cholesterol concentration and incident prostate cancer in the CLUE II Cohort. Cancer Causes Control21(1), 61–68 (2010).
   PubMed Web of Science ®Google Scholar
• Ulmer H, Borena W, Rapp K et al. Serum triglyceride concentrations and cancer risk in a large cohort study in Austria. Br. J. Cancer101(7), 1202–1206 (2009).
   PubMed Web of Science ®Google Scholar
• Van Hemelrijck M, Garmo H, Holmberg L et al. Prostate cancer risk in the Swedish AMORIS study: the interplay among triglycerides, total cholesterol, and glucose. Cancer117(10), 2086–2095 (2011).
   PubMed Web of Science ®Google Scholar
• Henriksson P, Eriksson M, Ericsson S et al. Hypocholesterolaemia and increased elimination of low-density lipoproteins in metastatic cancer of the prostate. Lancet2(8673), 1178–1180 (1989).
   Google Scholar
• Chen SS, Chen KK, Lin AT, Chang YH, Wu HH, Chang LS. Correlation between pretreatment serum biochemical markers and treatment outcome for prostatic cancer with bony metastasis. J. Chin. Med. Assoc.72(6), 301–306 (2009).
   Google Scholar
• Thysell E, Surowiec I, Hornberg E et al. Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol. PLoS ONE5(12), e14175 (2010).
   PubMed Web of Science ®Google Scholar
• Platz EA, Leitzmann MF, Visvanathan K et al. Statin drugs and risk of advanced prostate cancer. J. Natl Cancer Inst.98(24), 1819–1825 (2006).
   PubMed Web of Science ®Google Scholar
• Vainio P, Lehtinen L, Mirtti T et al. Phospholipase PLA2G7, associated with aggressive prostate cancer, promotes prostate cancer cell migration and invasion and is inhibited by statins. Oncotarget2(12), 1176–1190 (2011).
   PubMedGoogle Scholar
• Banez LL, Klink JC, Jayachandran J et al. Association between statins and prostate tumor inflammatory infiltrate in men undergoing radical prostatectomy. Cancer Epidemiol. Biomarkers Prev.19(3), 722–728 (2010).
   Google Scholar
• Freeman MR, Solomon KR. Cholesterol and prostate cancer. J. Cell. Biochem.91(1), 54–69 (2004).
   PubMed Web of Science ®Google Scholar
• Bonovas S, Filioussi K, Tsavaris N, Sitaras NM. Statins and cancer risk: a literature-based meta-analysis and meta-regression analysis of 35 randomized controlled trials. J. Clin. Oncol.24(30), 4808–4817 (2006).
   PubMed Web of Science ®Google Scholar
• Kuoppala J, Lamminpaa A, Pukkala E. Statins and cancer: a systematic review and meta-analysis. Eur. J. Cancer44(15), 2122–2132 (2008).
   PubMed Web of Science ®Google Scholar
• Bonovas S, Filioussi K, Sitaras NM. Statin use and the risk of prostate cancer: a metaanalysis of 6 randomized clinical trials and 13 observational studies. Int. J. Cancer123(4), 899–904 (2008).
   PubMed Web of Science ®Google Scholar
• Agalliu I, Salinas CA, Hansten PD, Ostrander EA, Stanford JL. Statin use and risk of prostate cancer: results from a population-based epidemiologic study. Am. J. Epidemiol.168(3), 250–260 (2008).
   PubMed Web of Science ®Google Scholar
• Friedman GD, Flick ED, Udaltsova N, Chan J, Quesenberry CP Jr, Habel LA. Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol. Drug Saf.17(1), 27–36 (2008).
   PubMed Web of Science ®Google Scholar
• Haukka J, Sankila R, Klaukka T et al. Incidence of cancer and statin usage – record linkage study. Int. J. Cancer126(1), 279–284 (2010).
   PubMed Web of Science ®Google Scholar
• Boudreau DM, Yu O, Buist DS, Miglioretti DL. Statin use and prostate cancer risk in a large population-based setting. Cancer Causes Control19(7), 767–774 (2008).
   PubMed Web of Science ®Google Scholar
• Farwell WR, Scranton RE, Lawler EV et al. The association between statins and cancer incidence in a veterans population. J. Natl Cancer Inst.100(2), 134–139 (2008).
   PubMed Web of Science ®Google Scholar
• Murtola TJ, Tammela TL, Lahtela J, Auvinen A. Cholesterol-lowering drugs and prostate cancer risk: a population-based case–control study. Cancer Epidemiol. Biomarkers Prev.16(11), 2226–2232 (2007).
   PubMed Web of Science ®Google Scholar
• Jacobs EJ, Rodriguez C, Bain EB, Wang Y, Thun MJ, Calle EE. Cholesterol-lowering drugs and advanced prostate cancer incidence in a large U.S. cohort. Cancer Epidemiol. Biomarkers Prev.16(11), 2213–2217 (2007).
   PubMed Web of Science ®Google Scholar
• Loeb S, Kan D, Helfand BT, Nadler RB, Catalona WJ. Is statin use associated with prostate cancer aggressiveness? BJU Int.105(9), 1222–1225 (2010).
   Google Scholar
• Gutt R, Tonlaar N, Kunnavakkam R, Karrison T, Weichselbaum RR, Liauw SL. Statin use and risk of prostate cancer recurrence in men treated with radiation therapy. J. Clin. Oncol.28(16), 2653–2659 (2010).
   PubMed Web of Science ®Google Scholar
• Hamilton RJ, Banez LL, Aronson WJ et al. Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Cancer116(14), 3389–3398 (2010).
   PubMed Web of Science ®Google Scholar
• Hamilton RJ, Goldberg KC, Platz EA, Freedland SJ. The influence of statin medications on prostate-specific antigen levels. J. Natl Cancer Inst.100(21), 1511–1518 (2008).
   PubMedGoogle Scholar
• Mondul AM, Selvin E, De Marzo AM, Freedland SJ, Platz EA. Statin drugs, serum cholesterol, and prostate-specific antigen in the National Health and Nutrition Examination Survey 2001–2004. Cancer Causes Control21(5), 671–678 (2010).
   PubMed Web of Science ®Google Scholar
• Pazzaglia S, Saran A, Pariset L et al. Sensitivity of C3H 10T1/2 cells to radiation-induced killing and neoplastic transformation as a function of cell cycle. Int. J. Radiat. Biol.69(1), 57–65 (1996).
   PubMed Web of Science ®Google Scholar
• Langley RE, Quartuccio SG, Kennealey PT, Coleman CN, Bump EA. Effect of cell cycle stage, dose rate and repair of sublethal damage on radiation-induced apoptosis in F9 teratocarcinoma cells. Radiat. Res.144(1), 90–96 (1995).
   PubMed Web of Science ®Google Scholar
• Keyomarsi K, Sandoval L, Band V, Pardee AB. Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res.51(13), 3602–3609 (1991).
   PubMed Web of Science ®Google Scholar
• Sivaprasad U, Abbas T, Dutta A. Differential efficacy of 3-hydroxy-3-methylglutaryl CoA reductase inhibitors on the cell cycle of prostate cancer cells. Mol. Cancer Ther.5(9), 2310–2316 (2006).
   PubMed Web of Science ®Google Scholar
• Miller AC, Kariko K, Myers CE, Clark EP, Samid D. Increased radioresistance of EJras-transformed human osteosarcoma cells and its modulation by lovastatin, an inhibitor of p21ras isoprenylation. Int. J. Cancer53(2), 302–307 (1993).
   PubMed Web of Science ®Google Scholar
• Moyad MA, Merrick GS, Butler WM et al. Statins, especially atorvastatin, may favorably influence clinical presentation and biochemical progression-free survival after brachytherapy for clinically localized prostate cancer. Urology66(6), 1150–1154 (2005).
   PubMed Web of Science ®Google Scholar
• Soto DE, Daignault S, Sandler HM, Ray ME. No effect of statins on biochemical outcomes after radiotherapy for localized prostate cancer. Urology73(1), 158–162 (2009).
   PubMed Web of Science ®Google Scholar
• Mondul AM, Caffo B, Platz EA. Minimal detection bias in the inverse association between statin drug use and advanced prostate cancer risk: a simulation study. Cancer Epidemiol.35(4), e6–e11 (2011).
   Google Scholar
• Tande AJ, Platz EA, Folsom AR. The metabolic syndrome is associated with reduced risk of prostate cancer. Am. J. Epidemiol.164(11), 1094–1102 (2006).
   PubMed Web of Science ®Google Scholar
• Chen Y, Hughes-Fulford M. Human prostate cancer cells lack feedback regulation of low-density lipoprotein receptor and its regulator, SREBP2. Int. J. Cancer91(1), 41–45 (2001).
   PubMed Web of Science ®Google Scholar
• Zhuang L, Kim J, Adam RM, Solomon KR, Freeman MR. Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J. Clin. Invest.115(4), 959–968 (2005).
   PubMed Web of Science ®Google Scholar
• Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer2(7), 489–501 (2002).
   PubMed Web of Science ®Google Scholar
• Zhuang L, Lin J, Lu ML, Solomon KR, Freeman MR. Cholesterol-rich lipid rafts mediate akt-regulated survival in prostate cancer cells. Cancer Res.62(8), 2227–2231 (2002).
   PubMed Web of Science ®Google Scholar
• Huggins C, Hodges CV. Studies of prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phophatases in metastatic carcinoma of the prostate. Cancer Res.1, 293–297 (1941).
   Google Scholar
• Cinar B, Mukhopadhyay NK, Meng G, Freeman MR. Phosphoinositide 3-kinase-independent non-genomic signals transit from the androgen receptor to Akt1 in membrane raft microdomains. J. Biol. Chem.282(40), 29584–29593 (2007).
   PubMed Web of Science ®Google Scholar
• Swinnen JV, Ulrix W, Heyns W, Verhoeven G. Coordinate regulation of lipogenic gene expression by androgens: evidence for a cascade mechanism involving sterol regulatory element binding proteins. Proc. Natl Acad. Sci. USA94(24), 12975–12980 (1997).
   PubMed Web of Science ®Google Scholar
• Swinnen JV, Van Veldhoven PP, Esquenet M, Heyns W, Verhoeven G. Androgens markedly stimulate the accumulation of neutral lipids in the human prostatic adenocarcinoma cell line LNCaP. Endocrinology137(10), 4468–4474 (1996).
   Google Scholar
• Roy M, Kung HJ, Ghosh PM. Statins and prostate cancer: role of cholesterol inhibition vs. prevention of small GTP-binding proteins. Am. J. Cancer Res.1(4), 542–561 (2011).
   PubMed Web of Science ®Google Scholar
• Ghosh PM, Ghosh-Choudhury N, Moyer ML et al. Role of RhoA activation in the growth and morphology of a murine prostate tumor cell line. Oncogene18(28), 4120–4130 (1999).
   PubMed Web of Science ®Google Scholar
• Somlyo AV, Bradshaw D, Ramos S, Murphy C, Myers CE, Somlyo AP. Rho-kinase inhibitor retards migration and in vivo dissemination of human prostate cancer cells. Biochem. Biophys. Res. Commun.269(3), 652–659 (2000).
   PubMed Web of Science ®Google Scholar
• Hoque A, Chen H, Xu XC. Statin induces apoptosis and cell growth arrest in prostate cancer cells. Cancer Epidemiol. Biomarkers Prev.17(1), 88–94 (2008).
   PubMed Web of Science ®Google Scholar
• Parikh A, Childress C, Deitrick K, Lin Q, Rukstalis D, Yang W. Statin-induced autophagy by inhibition of geranylgeranyl biosynthesis in prostate cancer PC3 cells. Prostate70(9), 971–981 (2010).
   PubMed Web of Science ®Google Scholar
• Leon C, Hill JS, Wasan KM. Potential role of acyl-coenzyme A:cholesterol transferase (ACAT) inhibitors as hypolipidemic and antiatherosclerosis drugs. Pharm. Res.22(10), 1578–1588 (2005).
   PubMed Web of Science ®Google Scholar
• Locke JA, Wasan KM, Nelson CC, Guns ES, Leon CG. Androgen-mediated cholesterol metabolism in LNCaP and PC-3 cell lines is regulated through two different isoforms of acyl-coenzyme A: cholesterol acyltransferase (ACAT). Prostate68(1), 20–33 (2008).
   PubMed Web of Science ®Google Scholar
• Eberlin LS, Dill AL, Costa AB et al. Cholesterol sulfate imaging in human prostate cancer tissue by desorption electrospray ionization mass spectrometry. Anal. Chem.82(9), 3430–3434 (2010).
   Web of Science ®Google Scholar
• Kiguchi K, Iwamori M, Yamanouchi S, Ishiwata I, Saga M, Amemiya A. Coexpression of cholesterol sulfate and cytokeratin as tumor markers in well-differentiated squamous cell carcinoma of the human uterine cervix. Clin. Cancer Res.4(12), 2985–2990 (1998).
   Google Scholar
• Rearick JI, Stoner GD, George MA, Jetten AM. Cholesterol sulfate accumulation in tumorigenic and nontumorigenic rat esophageal epithelial cells: evidence for defective differentiation control in tumorigenic cells. Cancer Res.48(18), 5289–5295 (1988).
   Google Scholar
• Epstein EH, Williams ML, Elias PM. The epidermal cholesterol sulfate cycle. J. Am. Acad. Dermatol.10(5 Pt 1), 866–868 (1984).
   PubMed Web of Science ®Google Scholar
• Roberts KD, Bandi L, Calvin HI, Drucker WD, Lieberman S. Evidence that steroid sulfates serve as biosynthetic intermediates. IV. Conversion of cholesterol sulfate in vivo to urinary C19 and C21 steroidal sulfates. Biochemistry3, 1983–1988 (1964).
   Google Scholar
• Roberts KD, Bandi L, Lieberman S. The conversion of cholesterol-3H-sulfate-35S into pregnenolone-3H-sulfate-35S by sonicated bovine adrenal mitochondria. Biochem. Biophys. Res. Commun.29, 6 (1967).
   Google Scholar
• Young DG, Hall PF. The side-chain cleavage of cholesterol and cholesterol sulfate by enzymes from bovine adrenocortical mitochondria. Biochemistry8(7), 2987–2997 (1969).
   PubMed Web of Science ®Google Scholar
• Hochberg RB, Ladany S, Welch M, Lieberman S. Cholesterol and cholesterol sulfate as substrates for the adrenal side-chain cleavage enzyme. Biochemistry13(9), 1938–1945 (1974).
   PubMed Web of Science ®Google Scholar
• Montgomery RB, Mostaghel EA, Vessella R et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res.68(11), 4447–4454 (2008).
   PubMed Web of Science ®Google Scholar
• Ponec M, Havekes L, Kempenaar J, Vermeer BJ. Cultured human skin fibroblasts and keratinocytes: differences in the regulation of cholesterol synthesis. J. Invest. Dermatol.81(2), 125–130 (1983).
   PubMed Web of Science ®Google Scholar
• Bleau G, Lalumiure G, Chapdelaine A, Roberts K. Red cell surface structure. Stabilization by cholesterol sulfate as evidenced by scanning electron microscopy. Biochim. Biophys. Acta375(2), 220–223 (1975).
   Google Scholar
• Bleau G, Bodley FH, Longpre J, Chapdelaine A, Roberts KD. Cholesterol sulfate. I. Occurrence and possible biological function as an amphipathic lipid in the membrane of the human erythrocyte. Biochim. Biophys. Acta352(1), 1–9 (1974).
   PubMedGoogle Scholar
• Bill-Axelson A, Holmberg L, Ruutu M et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N. Engl. J. Med.364(18), 1708–1717 (2011).
   PubMed Web of Science ®Google Scholar